Anvimo 240mg Tablet is an antiviral drug that contains letermovir as its active component. It falls under the category of antiviral agents and is specifically classified as a cytomegalovirus (CMV) DNA terminase inhibitor. This tablet is mainly utilized to prevent CMV infection in patients who have recently had an allogeneic hematopoietic stem cell transplant (HSCT) and are at an increased risk of CMV reactivation.
The mechanism of Anvimo 240mg Tablet involves the inhibition of the CMV DNA terminase complex, which is essential for the replication of the virus. It is generally prescribed for adult patients who are CMV-seropositive following transplantation to minimize the risk of viral complications. However, it is important to note that this medication does not treat existing CMV infections.
Patients using this medication must adhere to strict safety guidelines. It is contraindicated for individuals with a known hypersensitivity to letermovir or any of its components. Furthermore, it is not advisable to use this medication alongside certain drugs due to the potential for serious drug interactions. Healthcare providers recommend caution for pregnant or breastfeeding women, individuals with liver issues, and those who consume alcohol.
Anvimo 240mg Tablet is FDA-approved for the prevention of cytomegalovirus (CMV) infection in adult patients who:
Have undergone allogeneic hematopoietic stem cell transplantation (HSCT)
Are CMV-seropositive, meaning they have previously been exposed to the virus
This medication is used prophylactically and should not be used to treat an active CMV infection.
Anvimo 240mg Tablet functions by blocking the CMV DNA terminase complex, a key component required for viral replication. Unlike conventional antiviral drugs that target DNA polymerase, this medication disrupts viral DNA processing and packaging, ultimately preventing the virus from multiplying and spreading in the body.
By stopping CMV replication early in the process, this drug significantly lowers the risk of CMV disease in transplant recipients. The unique mechanism of action makes it highly effective while reducing the likelihood of cross-resistance seen with other CMV treatments. Due to its targeted action, it is well tolerated with a lower risk of severe toxicity compared to older antiviral medications.
Serious drug interactions can alter the effectiveness of Anvimo 240mg Tablet or increase the risk of side effects. Patients should inform their doctor about all medications, including herbal and over-the-counter drugs, before starting this medication.
Notable Drug Interactions:
Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Sirolimus): Letermovir can increase blood levels of these drugs, requiring dose adjustments.
Statins (e.g., Simvastatin, Atorvastatin): Increased risk of myopathy or rhabdomyolysis when taken together. Avoid co-administration or monitor closely.
Anticonvulsants (e.g., Phenytoin, Carbamazepine): May reduce Anvimo 240mg Tablet effectiveness, requiring alternative options.
Rifampin and St. John’s Wort: These reduce drug efficacy and should be avoided.
Oral Contraceptives: Letermovir may lower the effectiveness of hormonal birth control, necessitating additional contraceptive methods.
The usual recommended dosage of Anvimo 240mg Tablet for CMV prophylaxis is once daily. However, if taken in combination with cyclosporine, the dose is reduced to 240 mg daily to prevent excessive drug levels. This medication is available in oral tablets and intravenous (IV) infusion forms. Oral tablets should be swallowed whole with or without food, while the IV infusion must be administered under medical supervision to ensure proper dosing and monitoring.
Anvimo 240mg contains Letermovir, an antiviral agent used to prevent cytomegalovirus (CMV) infection in patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and are CMV-seropositive
Common Side Effects:
Nausea
Fatigue
Headache
Diarrhea
Abdominal pain
Serious Side Effects:
Irregular heartbeat
Swelling in legs or feet
Unexplained bleeding or bruising
Severe allergic reactions (rash, breathing difficulty)
Not for active CMV infections — used only as a preventive measure
Avoid in patients with hypersensitivity to Letermovir
Use with caution in:
Pregnant or breastfeeding women
Patients with liver impairment
Those consuming alcohol
Fact Box of ANVIMO 240
Molecule Name: Letermovir
Therapeutic Class: CMV DNA terminase inhibitor
Pharmacological Class: Antiviral agent
Indications:
Prevention of CMV infection in HSCT patients
Disclaimer
At Medfast, we’re dedicated to bringing you accurate, trustworthy, and expert-vetted health information. Our primary goal is to ensure you receive content that you can rely on.
It’s crucial to understand that everything on this website is for general information purposes only. This content is not a substitute for professional medical advice, diagnosis, or treatment. We can’t stress enough the importance of consulting with your own doctor. They are the only ones who can provide tailored advice for your specific health concerns or medication questions.
Please, never ignore or delay seeking professional medical advice because of something you’ve read here. Our fundamental mission is to support and enhance the doctor-patient relationship, not to replace it.
All Substitutes
No related products found.
2000+ products
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
Secure Payment
100% secure and trusted payment protection
Easy Return
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.